Acute respiratory distress syndrome (ARDS) is characterized by a rapid‐onset respiratory
failure with a mortality rate of approximately 40%. This physiologic inflammatory process is …

Antiplatelet therapy is an attractive treatment option for critically ill patients. However, more
evidence on the benefit of this therapy is required. We searched the PubMed and Embase …

Evidence is emerging that platelets are major contributors to innate immune responses in
conditions such as acute lung injury (ALI). Platelets form heterotypic aggregates with …

The acute respiratory distress syndrome (ARDS) is a serious and common complication of
multiple medical and surgical interventions, with sepsis, pneumonia, and aspiration of …

Acute lung injury (ALI) and the acute respiratory distress syndrome (ARDS) are serious
complications of acute illness and injury, associated with an inpatient mortality of up to 40 …

The development of acute respiratory distress syndrome (ARDS) carries significant risk of
morbidity and mortality. To date, pharmacological therapy has been largely ineffective for …

Platelet activation plays an important role in the development of sepsis. During sepsis,
platelet activation leads to endothelial cell injury and promotes neutrophil extracellular trap …

Background. Sepsis is characterized by dysfunctional activation of platelets, and antiplatelet
therapy could improve the outcomes of septic patients. Methods. We performed a …

Acute respiratory distress syndrome (ARDS) is a heterogeneous cause of respiratory failure
that has a rapid onset, a high mortality rate, and for which there is no effective …

Acute respiratory distress syndrome (ARDS) is characterized by acute diffuse lung injury,
which results in increased pulmonary vascular permeability and loss of aerated lung tissue …